{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:51:34Z","timestamp":1781949094872,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12282-026-01871-2","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T06:56:24Z","timestamp":1779519384000},"page":"928-937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1\u20133 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-7599","authenticated-orcid":false,"given":"Takeshi","family":"Murata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Watase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinako","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nakashoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Ohgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayako","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"1871_CR1","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055. https:\/\/doi.org\/10.1093\/jnci\/dju055.","journal-title":"J Natl Cancer Inst"},{"key":"1871_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12282-010-0209-6","volume":"18","author":"K Shibuta","year":"2011","unstructured":"Shibuta K, Ueo H, Furusawa H, Komaki K, Rai Y, Sagara Y, et al. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4266 Japanese women with breast cancer. Breast Cancer. 2011;18:292\u20138. https:\/\/doi.org\/10.1007\/s12282-010-0209-6.","journal-title":"Breast Cancer"},{"key":"1871_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5.","journal-title":"Lancet Oncol"},{"key":"1871_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, O\u2019Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987\u201393. https:\/\/doi.org\/10.1200\/JCO.23.01994.","journal-title":"J Clin Oncol"},{"key":"1871_CR5","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1245\/s10434-010-1451-z","volume":"18","author":"PD Gobardhan","year":"2011","unstructured":"Gobardhan PD, Elias SG, Madsen EVE, van Wely B, van den Wildenberg F, Theunissen EBM, et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study. Ann Surg Oncol. 2011;18:1657\u201364. https:\/\/doi.org\/10.1245\/s10434-010-1451-z.","journal-title":"Ann Surg Oncol"},{"key":"1871_CR6","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1200\/JCO.2008.19.0686","volume":"27","author":"NM Hansen","year":"2009","unstructured":"Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009;27:4679\u201384. https:\/\/doi.org\/10.1200\/JCO.2008.19.0686.","journal-title":"J Clin Oncol"},{"key":"1871_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38:1346\u201366. https:\/\/doi.org\/10.1200\/JCO.19.02309.","journal-title":"J Clin Oncol"},{"key":"1871_CR8","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984.","journal-title":"J Clin Oncol"},{"key":"1871_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"1871_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC, The American Joint Committee on Cancer. The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471\u20134. https:\/\/doi.org\/10.1245\/s10434-010-0985-4.","journal-title":"Ann Surg Oncol"},{"key":"1871_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018;25:1783\u20135. https:\/\/doi.org\/10.1245\/s10434-018-6486-6.","journal-title":"Ann Surg Oncol"},{"key":"1871_CR12","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38:3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514.","journal-title":"J Clin Oncol"},{"key":"1871_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa0904832","volume":"361","author":"M de Boer","year":"2009","unstructured":"de Boer M, van Deurzen CHM, van Dijck JAAM, Borm GF, van Diest PJ, Adang EMM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653\u201363. https:\/\/doi.org\/10.1056\/NEJMoa0904832.","journal-title":"N Engl J Med"},{"key":"1871_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","volume":"20","author":"M Sol\u00e1","year":"2013","unstructured":"Sol\u00e1 M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000. Ann Surg Oncol. 2013;20:120\u20137. https:\/\/doi.org\/10.1245\/s10434-012-2569-y.","journal-title":"Ann Surg Oncol"},{"key":"1871_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30380-2.","journal-title":"Lancet Oncol"},{"key":"1871_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10549-021-06341-1","volume":"189","author":"SZ Lim","year":"2021","unstructured":"Lim SZ, Kusumawidjaja G, Mohd Ishak HM, Tan BKT, Tan SY, Hamzah JL, et al. Outcomes of stage I and II breast cancer with nodal micrometastases treated with mastectomy without axillary therapy. Breast Cancer Res Treat. 2021;189:837\u201343. https:\/\/doi.org\/10.1007\/s10549-021-06341-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1871_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.clbc.2022.01.001","volume":"22","author":"EC Merfeld","year":"2022","unstructured":"Merfeld EC, Burr AR, Brickson C, Neuman HB, Anderson BM. De-escalating locoregional therapy for axillary micrometastases in breast cancer: How much is too much? Clin Breast Cancer. 2022;22:336\u201342. https:\/\/doi.org\/10.1016\/j.clbc.2022.01.001.","journal-title":"Clin Breast Cancer"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01871-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:22:22Z","timestamp":1781947342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01871-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1871"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01871-2","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The National Cancer Center Hospital Review Board and Ethical Committee approved this study (approval no. 2017\u2009\u2212\u2009278).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The requirement for informed consent was waived owing to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}